Response to imatinib in a patient with chronic myeloid leukemia simultaneously expressing p190BCR-ABL oncoprotein and JAK2V617F mutation

Leukemia Research

Volumn 34, Issue 1, 2010, Pages

  Caocci, G ^a   S Atzeni, ^a   Orru N ^a   Littera, R ^a   Culurgioni, F ^b   Marongiu, F ^a   La Nasa, G ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Armando Businco Cancer Center   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; IMATINIB; JANUS KINASE 2; MESSENGER RNA; ONCOPROTEIN; P190 BCR ABL PROTEIN; PROTEIN P190; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; AGED; BONE MARROW BIOPSY; CASE REPORT; CELL HYPERPLASIA; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION 9; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; GENETIC TRANSCRIPTION; GOOD GENERAL CONDITION; HUMAN; KARYOTYPE 46,XY; LETTER; LEUKOCYTOSIS; MALE; METAPHASE CHROMOSOME; NUCLEOTIDE SEQUENCE; ONCOGENE; PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SPLENOMEGALY;

AGED; ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MUTATION; PIPERAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 73249137522     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.08.009     Document Type: Letter

References (11)

1. Goldman J.M., and Melo J.V. Chronic myeloid leukaemia-advances in biology and new approaches to treatment. N Engl J Med 349 (2003) 1451-1464
2. Campbell P.J., and Green A.R. The myeloproliferative disorders. N Engl J Med 355 (2006) 2452-2466
3. Bornhauser M., Mohr B., Oelschlaegel U., Bornhauser P., Jacki S., Ehninger G., et al. Concurrent JAK2 (V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 21 (2007) 1824-1826
4. V617F mutation. Blood 109 (2007) 4106-4107
5. V617F and BCR/ABL. Eur J Haematol 81 (2008) 75-76
6. Ohsaka A., Shiina S., Kobayashi M., Kudo H., and Kawaguchi R. Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL). Intern Med 41 (2002) 1183-1187
7. Van Dongen J.J., Macintyre E.A., Gabert J.A., Delabesse E., Rossi V., Saglio G., et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13 (1999) 1901-1928
8. Steensma D.P., Dewald G.W., Lasho T.L., Powell H.L., McClure R.F., Levine R.L., et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood 106 (2005) 1207-1209
9. Hur M., Lee D.S., Cho H.I., Jung S., and park S. Lymphoid blast crisis is a natural course of minor breakpoint cluster region positive chronic myelogenous leukemia. Lab Hematol 7 (2001) 65-67
10. BCRABL chronic myeloid leukaemia: the missing link with chronic myelomonocytic leukaemia?. Leukemia 8 (1994) 208-211
11. V617F era. Hematol Am Soc Hematol Educ Program (2006) 240-245